Radiopharm Theranostics Ltd (RADX)
About Radiopharm Theranostics Ltd
Radiopharm Theranostics Ltd is an Australian-based clinical-stage radiotherapeutics company targeting cancer. The company has a pipeline of approximately four licensed platform technologies, with diagnostic and therapeutic applications at both the pre-clinical and clinical stages of development. The company is engaged in research, development, and commercialization of health technologies.
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
Financial summary
- Market cap
- $34.1M
15-minute delayed · data by Polygon.io
Past year · hover for prices
52-week range
- Market cap
- $34.1M
- Shares outstanding
- 9.6M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- Nov 27, 2024
Radiopharm Theranostics Ltd (RADX) Stock Price
- Trading 67% below its 52-week high.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review Radiopharm Theranostics Ltd.
Write a review
News about Radiopharm Theranostics Ltd
News & sentiment via Polygon.io
Radiopharm Theranostics Ltd: frequently asked questions
Is Radiopharm Theranostics Ltd an American company?
Radiopharm Theranostics Ltd is a US-based company, listed in the americancompanies.com directory of American companies. Its American-origin credentials have not yet been independently verified.
Is Radiopharm Theranostics Ltd publicly traded?
Yes — Radiopharm Theranostics Ltd is a publicly traded company. Its stock trades under the ticker symbol RADX on the NASDAQ.
What does Radiopharm Theranostics Ltd do?
Radiopharm Theranostics Ltd is an American Pharmaceuticals company in the Health & Beauty sector.
